Mitsubishi UFJ Asset Management UK Ltd. Grows Stock Position in LivaNova PLC (NASDAQ:LIVN)

Mitsubishi UFJ Asset Management UK Ltd. boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 11.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,000 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in LivaNova were worth $998,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its position in shares of LivaNova by 88.6% during the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after buying an additional 19,783 shares in the last quarter. Driehaus Capital Management LLC grew its holdings in LivaNova by 64.7% during the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after acquiring an additional 213,749 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after purchasing an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova in the 2nd quarter valued at $16,614,000. Finally, Quantbot Technologies LP purchased a new stake in shares of LivaNova during the 1st quarter worth $994,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN traded up $0.35 during mid-day trading on Friday, reaching $53.57. 330,406 shares of the company’s stock were exchanged, compared to its average volume of 625,226. The business’s fifty day simple moving average is $49.75 and its 200-day simple moving average is $53.24. The stock has a market capitalization of $2.90 billion, a PE ratio of -89.28 and a beta of 1.00. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.15. The company had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, equities research analysts expect that LivaNova PLC will post 2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Needham & Company LLC increased their target price on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $55.00 to $66.00 in a research report on Tuesday, September 17th. Stifel Nicolaus upped their price target on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group started coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova has a consensus rating of “Buy” and an average target price of $69.83.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.